Advertisement

Topics

These highlights do not include all the information needed to use CLOBETASOL PROPIONATE FOAM safely and effectively. See full prescribing information for CLOBETASOL PROPIONATE FOAM.  CLOBETASOL PROPIONATE foam, 0.05% For topical use Initial U.S. Approval | Clobetasol Propionate [Mylan Pharmaceuticals Inc.] | BioPortfolio

18:46 EST 26th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Clobetasol propionate foam is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years and older.

Clobetasol Propionate Foam, 0.05% contains 0.5 mg of clobetasol propionate, USP per gram.

None.

Clobetasol propionate foam has been shown to suppress the hypothalamic-pituitary-adrenal (HPA) axis.

Systemic absorption of clobetasol propionate has caused reversible HPA axis suppression with the potential for clinical glucocorticoid insufficiency. This may occur during treatment or upon withdrawal of the topical corticosteroid. Use of clobetasol propionate foam for longer than 2 weeks may suppress the immune system [see Nonclinical Toxicology (13.1)].

In a trial including 37 subjects ages 12 years and older with atopic dermatitis of at least 30% body surface area (BSA), adrenal suppression was identified in 6 out of 37 subjects (16.2%) after 2 weeks of treatment with clobetasol propionate [see Clinical Pharmacology (12.2)].

Because of the potential for systemic absorption, use of clobetasol propionate may require that patients be periodically evaluated for HPA axis suppression. Factors that predispose a patient using a topical corticosteroid to HPA axis suppression include the use of more potent steroids, use over large surface areas, use over prolonged periods, use under occlusion, use on an altered skin barrier, and use in patients with liver failure.

An adrenocorticotrophic hormone (ACTH) stimulation test may be helpful in evaluating patients for HPA axis suppression. If HPA axis suppression is documented, an attempt should be made to gradually withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Manifestations of adrenal insufficiency may require systemic corticosteroids. Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids.

Cushing’s syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids.

Use of more than 1 corticosteroid-containing product at the same time may increase the total systemic corticosteroid exposure.

Pediatric patients may be more susceptible to systemic toxicity from equivalent doses because of their larger skin surface-to-body mass ratios [see Use in Specific Populations (8.4)].

Local adverse reactions may be more likely to occur with occlusive use, prolonged use, or use of higher potency corticosteroids. Reactions may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria. Some local adverse reactions may be irreversible.

Allergic contact dermatitis to any component of topical corticosteroids is usually diagnosed by a failure to heal rather than a clinical exacerbation. Clinical diagnosis of allergic contact dermatitis can be confirmed by patch testing.

If irritation develops, treatment with clobetasol propionate foam should be discontinued and appropriate therapy instituted.

Use of topical corticosteroids, including clobetasol propionate foam, may increase the risk of posterior subcapsular cataracts and glaucoma. Cataracts and glaucoma have been reported postmarketing with the use of topical corticosteroids, including topical clobetasol products [see Adverse Reactions (6.2)].

Avoid contact of clobetasol propionate foam with eyes. Advise patients to report any visual symptoms and consider referral to an ophthalmologist for evaluation.

Concomitant skin infections should be treated with an appropriate antimicrobial agent. If the infection persists, clobetasol propionate foam should be discontinued until the infection has been adequately treated.

The propellant in clobetasol propionate foam is flammable. Avoid fire, flame, or smoking during and immediately following application. Do not puncture and/or incinerate the containers. Do not expose containers to heat and/or store at temperatures above 120°F (49°C).

The following adverse reactions are discussed in greater detail in other sections of the labeling:

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

In controlled clinical trials involving 821 subjects exposed to clobetasol propionate foam and vehicle foam, the pooled incidence of local adverse reactions in trials for atopic dermatitis and psoriasis with clobetasol propionate foam was 1.9% for application site atrophy and 1.6% for application site reaction. Most local adverse events were rated as mild to moderate and they were not affected by age, race, or gender.

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

The following adverse reactions have been identified during post-approval use of clobetasol formulations: erythema, pruritus, burning, alopecia, and dryness.

The following additional local adverse reactions have been reported with topical corticosteroids: folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, irritation, striae, and miliaria. They may occur more frequently with the use of occlusive dressings and higher potency corticosteroids, such as clobetasol propionate.

Cushing’s syndrome has been reported in infants and adults as a result of prolonged use of topical clobetasol propionate formulations.

Ophthalmic adverse reactions may include cataracts, glaucoma, increased intraocular pressure, and central serous chorioretinopathy.

There are no available data on clobetasol propionate foam use in pregnant women to inform of a drug associated risk for adverse developmental outcomes.

Published data report a significantly increased risk of low birthweight with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy. Advise pregnant women of the potential risk to a fetus and to use clobetasol propionate foam on the smallest area of skin and for the shortest duration possible (see Data ).

In animal reproduction studies, increased malformations, such as cleft palate and skeletal abnormalities, were observed after subcutaneous administration of clobetasol propionate to pregnant mice and rabbits. No comparison of animal exposure with human exposure was computed.

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Multiple observational studies found no significant associations between maternal use of topical corticosteroids of any potency and congenital malformations, preterm delivery, or fetal mortality. However, when the dispensed amount of potent or very potent topical corticosteroid exceeded 300 g during the entire pregnancy, use was associated with an increase in low birth weight infants (adjusted RR, 7.74 [95% CI, 1.49–40.11]). In addition, a small cohort study, in which 28 sub-Saharan women using potent topical corticosteroids (27/28 used clobetasol propionate 0.05%) for skin lightening during pregnancy, noted a higher incidence of low birth weight infants in the exposed group. The majority of exposed subjects treated large areas of the body (a mean quantity of 60 g/month [range, 12–170 g]) over long periods of time.

Embryofetal development studies conducted with clobetasol propionate in mice using the subcutaneous route resulted in fetotoxicity at the highest dose tested (1 mg/kg) and malformations at all dose levels tested down to 0.03 mg/kg. Malformations seen included cleft palate and skeletal abnormalities.

In an embryofetal development study in rabbits, subcutaneous administration of clobetasol propionate resulted in malformations at doses of 0.003 and 0.01 mg/kg. Malformations seen included cleft palate, cranioschisis, and other skeletal abnormalities.

There is no information regarding the presence of clobetasol propionate in breast milk or its effects on the breastfed infant or on milk production. Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of clobetasol propionate could result in sufficient systemic absorption to produce detectable quantities in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for clobetasol propionate foam and any potential adverse effects on the breastfed infant from clobetasol propionate foam or from the underlying maternal condition.

To minimize potential exposure to the breastfed infant via breast milk, use clobetasol propionate foam on the smallest area of skin and for the shortest duration possible while breastfeeding. Advise breastfeeding women not to apply clobetasol propionate foam directly to the nipple and areola to avoid direct infant exposure.

Use in pediatric patients younger than 12 years is not recommended because of the risk of HPA axis suppression.

After two weeks of twice-daily treatment with clobetasol propionate foam, 7 of 15 subjects (47%) aged 6 to 11 years demonstrated HPA axis suppression. The laboratory suppression was transient; in all subjects serum cortisol levels returned to normal when tested 4 weeks post-treatment.

In 92 subjects aged 12 to 17 years, safety was similar to that observed in the adult population. Based on these data, no adjustment of dosage of clobetasol propionate foam in adolescent patients aged 12 to 17 years is warranted [see Warnings and Precautions (5.1)].

Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing’s syndrome when they are treated with topical corticosteroids. They are therefore also at greater risk of adrenal insufficiency during and/or after withdrawal of treatment.

HPA axis suppression, Cushing’s syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and an absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles (in infants), headaches, and bilateral papilledema. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

Adverse effects, including striae, have been reported with inappropriate use of topical corticosteroids in infants and children.

A limited number of subjects aged 65 years or older have been treated with clobetasol propionate foam (n = 58) in U.S. clinical trials. While the number of subjects is too small to permit separate analysis of efficacy and safety, the adverse reactions reported in this population were similar to those reported by younger subjects. Based on available data, no adjustment of dosage of clobetasol propionate foam in geriatric patients is warranted.

Topically applied clobetasol propionate foam can be absorbed in sufficient amounts to produce systemic effects.

Clobetasol propionate foam, is a white to off-white petrolatum-based emulsion aerosol foam, containing the active ingredient clobetasol propionate, USP, a synthetic corticosteroid for topical dermatologic use. Clobetasol, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity.

Clobetasol propionate is 21-chloro-9-fluoro-11ß,17-dihydroxy-16ß-methylpregna-1,4-diene-3,20-dione 17-propionate, with the empirical formula CHClFO, and a molecular weight of 466.97.

The following is the chemical structure:

Clobetasol propionate is a white to almost white crystalline powder, practically insoluble in water.

Each gram of clobetasol propionate foam contains 0.5 mg clobetasol propionate, USP. The foam also contains anhydrous citric acid, cetyl alcohol, cyclomethicone, isopropyl myristate, light mineral oil, polyoxyl 20 cetostearyl ether, potassium citrate monohydrate, propylene glycol, purified water, sorbitan monolaurate, white petrolatum, and phenoxyethanol as a preservative.

Clobetasol propionate foam is dispensed from an aluminum can pressurized with a hydrocarbon (propane/butane) propellant.

Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in corticosteroid-responsive dermatoses is unknown.

In a trial evaluating the potential for HPA axis suppression, using the cosyntropin stimulation test, clobetasol propionate foam demonstrated reversible adrenal suppression after two weeks of twice-daily use in subjects with atopic dermatitis of at least 30% body surface area (BSA). The proportion of subjects aged 12 years and older demonstrating HPA axis suppression was 16.2% (6 out of 37). In this trial HPA axis suppression was defined as serum cortisol level ≤18 mcg/dL 30 minutes post cosyntropin stimulation. The laboratory suppression was transient; in all subjects serum cortisol levels returned to normal when tested 4 weeks post treatment [see Warnings and Precautions (5.1), Use in Specific Populations (8.4)].

Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the product formulation and the integrity of the epidermal barrier. Occlusion, inflammation, and/or other disease processes in the skin may increase percutaneous absorption. The use of pharmacodynamic endpoints for assessing the systemic exposure of topical corticosteroids may be necessary due to the fact that circulating levels are often below the level of detection. Once absorbed through the skin, topical corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some corticosteroids and their metabolites are also excreted in the bile.

Following twice-daily application of clobetasol propionate foam for one week to 32 adult subjects with mild to moderate plaque-type psoriasis, mean peak plasma concentrations (±SD) of 59 ± 36 pg/mL of clobetasol were observed at around 5 hours post dose on Day 8.

Long-term animal studies have not been performed to evaluate the carcinogenic potential of clobetasol propionate foam or clobetasol propionate.

In a 90-day repeat-dose toxicity study in rats, topical administration of clobetasol propionate foam at dose concentrations from 0.001% to 0.1% or from 0.03 to 0.3 mg/kg/day of clobetasol propionate resulted in a toxicity profile consistent with long term exposure to corticosteroids including adrenal atrophy, histopathological changes in several organ systems indicative of severe immune suppression and opportunistic fungal and bacterial infections. A no observable adverse effect level could not be determined in this study. Although the clinical relevance of the findings in animals to humans is not clear, sustained glucocorticoid-related immune suppression may increase the risk of infection and possibly the risk for carcinogenesis.

Clobetasol propionate was non-mutagenic in the Ames test, the mouse lymphoma test, the Saccharomyces cerevisiae gene conversion assay, and the E. coli B WP2 fluctuation test. In the in vivo mouse micronucleus test, a positive finding was observed at 24 hours, but not at 48 hours, following oral administration at a dose of 2,000 mg/kg.

Studies in the rat following subcutaneous administration of clobetasol propionate at dosage levels up to 0.05 mg/kg per day revealed that the females exhibited an increase in the number of resorbed embryos and a decrease in the number of living fetuses at the highest dose.

In a randomized trial of subjects 12 years and older with moderate to severe atopic dermatitis, 251 subjects were treated with clobetasol propionate foam and 126 subjects were treated with vehicle foam. Subjects were treated twice daily for 2 weeks. At the end of treatment, 131 of 251 subjects (52%) treated with clobetasol propionate foam compared with 18 of 126 subjects (14%) treated with vehicle foam achieved treatment success. Treatment success was defined by an Investigator’s Static Global Assessment (ISGA) score of clear (0) or almost clear (1) with at least 2 grades improvement from baseline, and scores of absent or minimal (0 or 1) for erythema and induration/papulation.

In an additional randomized trial of subjects 12 years and older with mild to moderate plaque-type psoriasis, 253 subjects were treated with clobetasol propionate foam and 123 subjects were treated with vehicle foam. Subjects were treated twice daily for 2 weeks. At the end of treatment, 41 of 253 subjects (16%) treated with clobetasol propionate foam compared with 5 of 123 subjects (4%) treated with vehicle foam achieved treatment success. Treatment success was defined by an ISGA score of clear (0) or almost clear (1) with at least 2 grades improvement from baseline, scores of none or faint/minimal (0 or 1) for erythema and scaling, and a score of none (0) for plaque thickness.

Clobetasol Propionate Foam, 0.05% contains 0.5 mg of clobetasol propionate, USP per gram. The white emulsion aerosol foam is available as follows:

NDC 0378-8055-5050 g aluminum can

NDC 0378-8055-01100 g aluminum can

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]

FLAMMABLE. AVOID FIRE, FLAME OR SMOKING DURING AND IMMEDIATELY FOLLOWING APPLICATION. Contents under pressure. Do not puncture or incinerate. Do not expose to heat or store at temperatures above 120°F (49°C).

Keep out of reach of children.

See FDA-Approved Patient Labeling (Patient Information)

Effects on Endocrine System

Clobetasol propionate foam may cause HPA axis suppression. Advise patients that use of topical corticosteroids, including clobetasol propionate foam, may require periodic evaluation for HPA axis suppression. Topical corticosteroids may have other endocrine effects. Concomitant use of multiple corticosteroid-containing products may increase the total systemic exposure to topical corticosteroids. Patients should inform their physician(s) that they are using clobetasol propionate foam if surgery is contemplated [see Warnings and Precautions (5.1)].

Ophthalmic Adverse Reactions

Advise patients to report any visual symptoms to their healthcare providers [see Warnings and Precautions (5.3)].

Local Adverse Reactions

Report any signs of local adverse reactions to the physician. Advise patients that local reactions and skin atrophy are more likely to occur with occlusive use or prolonged use [see Warnings and Precautions (5.2)].

Pregnancy

Advise a pregnant woman that use of clobetasol propionate foam may cause fetal harm and to use clobetasol propionate foam on the smallest area of skin and for the shortest duration possible [see Use in Specific Populations (8.1)].

Lactation

Advise a woman to use clobetasol propionate foam on the smallest area of skin and for the shortest duration possible while breastfeeding. Advise breastfeeding women not to apply clobetasol propionate foam directly to the nipple and areola to avoid direct infant exposure [see Use in Specific Populations (8.2)].

Important Administration Instructions

Patients using topical corticosteroids should receive the following information and instructions:

The Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration.

Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

Manufactured by: DPT Laboratories, Ltd. San Antonio, TX 78215 U.S.A.

140952-0518

Revised: 5/2018DPT:ECLOBFOG:R2

on your face, underarms, or groin area if you have skin thinning (atrophy) at the treatment areaYou should not use clobetasol propionate foam for longer than 2 weeks in a row.You should not use more than 50 grams or 21 capfuls of clobetasol propionate foam in 1 week.have had irritation or other skin reaction to a steroid medicine in the past. have a skin infection. You may need medicine to treat the skin infection before using clobetasol propionate foam. have diabetes. have adrenal gland problems. have liver problems. plan to have surgery. are pregnant or plan to become pregnant. It is not known if clobetasol propionate foam will harm your unborn baby. If you use clobetasol propionate foam during pregnancy, use clobetasol propionate foam on the smallest area of skin and for the shortest time needed. are breastfeeding or plan to breastfeed. It is not known if clobetasol propionate passes into your breast milk. If you use clobetasol propionate foam while breastfeeding, use clobetasol propionate foam on the smallest area of skin and for the shortest time needed. Do not apply clobetasol propionate foam directly to the nipple and areola to avoid getting clobetasol propionate foam into your baby’s mouth. Tell your healthcare provider about all the medicine you take including prescription and over-the-counter medicines, vitamins, and herbal supplements. Do not use other products containing a corticosteroid medicine during treatment with clobetasol propionate foam without talking to your healthcare provider first.Use clobetasol propionate foam exactly as your healthcare provider tells you to use it. Apply a thin layer of clobetasol propionate foam to the affected area 2 times each day, 1 time in the morning and 1 time at night, or as directed by your healthcare provider. Do not bandage, wrap or cover your treated area unless your healthcare provider tells you to. Talk to your healthcare provider if your skin does not improve after 2 weeks of treatment with clobetasol propionate foam. Wash your hands after using clobetasol propionate foam. Clobetasol propionate foam can pass through your skin. Too much clobetasol propionate foam passing through your skin can cause adrenal glands to stop working. Cushing’s syndrome, a condition that happens when the body is exposed to too much of the hormone cortisol. High blood sugar (hyperglycemia) Vision problems. Clobetasol propionate foam may increase your chance of developing vision problems such as cataract(s) and glaucoma. Tell your healthcare provider if you develop blurred vision or other vision problems during your treatment with clobetasol propionate foam. Skin reactions at the treated site. Tell your healthcare provider if you get any skin reactions or skin infections. Effects on growth and weight in children. Your healthcare provider may do certain blood tests to check for side effects. The most common side effects of clobetasol propionate foam include: thinning of skin burning rednessitching drynessStore clobetasol propionate foam at room temperature between 68° to 77°F (20° to 25°C). Do not break through (puncture) clobetasol propionate foam can. Never throw the can into a fire, even if the can is empty. Do not store clobetasol propionate foam near heat or at temperatures above 120°F (49°C).Keep clobetasol propionate foam and all medicines out of the reach of children.
Clobetasol Propionate Foam
Important: For skin use only. Do not get clobetasol propionate foam in your eyes, mouth, or vagina.
What is clobetasol propionate foam? Clobetasol propionate foam is a prescription corticosteroid medicine used on the skin (topical) to treat people 12 years of age and older with certain skin conditions that cause red, flaky, and itchy skin. Clobetasol propionate foam is not recommended for use in children under 12 years of age. Clobetasol propionate foam should not be used:
Before using clobetasol propionate foam, tell your healthcare provider about all of your medical conditions, including if you:
How should I use clobetasol propionate foam? See the “Instructions for Use” for detailed information about the right way to apply clobetasol propionate foam.
What should I avoid while using clobetasol propionate foam? Clobetasol propionate foam is flammable. Avoid heat, flame, or smoking during and right after you apply clobetasol propionate foam to your skin.
What are the possible side effects of clobetasol propionate foam? Clobetasol propionate foam may cause serious side effects, including:
These are not all the side effects of clobetasol propionate foam. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store clobetasol propionate foam?
General information about the safe and effective use of clobetasol propionate foam Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use clobetasol propionate foam for a condition for which it was not prescribed. Do not give clobetasol propionate foam to other people, even if they have the same condition that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about clobetasol propionate foam that is written for health professionals.
What are the ingredients in clobetasol propionate foam? Active ingredient: clobetasol propionate Inactive ingredients: anhydrous citric acid, cetyl alcohol, cyclomethicone, isopropyl myristate, light mineral oil, polyoxyl 20 cetostearyl ether, potassium citrate monohydrate, propylene glycol, purified water, sorbitan monolaurate, white petrolatum, and phenoxyethanol as a preservative, pressurized with a hydrocarbon (propane/butane) propellant. Manufactured for: Mylan Pharmaceuticals Inc.,Morgantown, WV 26505 U.S.A. For more information, call Mylan at 1-877-446-3679 (1-877-4-INFO-RX).
Throw away any of the unused medicine that you dispensed out of the can.
INSTRUCTIONS FOR USE Clobetasol Propionate Foam
Important information: Clobetasol propionate foam is for use on the skin only. Do not get clobetasol propionate foam in your eyes, mouth, or vagina; if contact happens, rinse well with water.
How to apply clobetasol propionate foam
Figure A
Step 1: Before applying clobetasol propionate foam for the first time, break the tiny plastic piece at the base of the can's rim by gently pushing back (away from the piece) on the nozzle. (See Figure A).
Figure B
Step 2: Shake the can of clobetasol propionate foam before use. (See Figure B).
Figure C
Step 3: Turn the can of clobetasol propionate foam upside down and press the nozzle. See Figure C.
Figure D
Step 4: Press down on the actuator to dispense a small amount of clobetasol propionate foam into the palm of your hand. (See Figure D).
Figure E
Step 5: Apply a thin layer of clobetasol propionate foam to cover the affected area. Gently rub the foam into the affected area until the foam disappears. (See Figure E).
Step 6: Wash your hands after applying clobetasol propionate foam.

NDC 0378-8055-50

ClobetasolPropionateFoam0.05%

EmulsionFormulation

FOR TOPICAL USE ONLY.NOT FOR OPHTHALMIC, ORAL,OR INTRAVAGINAL USE.

Shake can before use.

Invert canand thenpress firmlyto dispense.

Description: Each gram of ClobetsolPropionate Foam contains 0.5 mgclobetasol propionate, USP.

The foam also contains anhydrouscitric acid, cetyl alcohol,cyclomethicone, isopropyl myristate,light mineral oil, polyoxyl 20cetostearyl ether, potassium citratemonohydrate, propylene glycol,purified water, sorbitan monolaurate,white petrolatum, and phenoxyethanolas a preservative, and is pressurizedwith a hydrocarbon (propane/butane)propellant.

Usual Dosage: Use only asprescribed by your physician. Seeaccompanying prescribinginformation.

Warning: FLAMMABLE. AVOID FIRE,FLAME, OR SMOKING DURING ANDIMMEDIATELY FOLLOWINGAPPLICATION.

Contents under pressure. Do notpuncture or incinerate. Do notexpose to heat or store attemperatures above 120°F (49°C).

Avoid contact with eyes or othermucous membranes. Keep this andall medication out of the reach ofchildren.

Store at 20° to 25°C (68° to 77°F).[See USP Controlled RoomTemperature.]

CFC FREE

Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

Manufactured by: DPT Laboratories, Ltd. San Antonio, TX 78215 U.S.A.

For more information, callMylan Pharmaceuticals Inc. at1-877-446-3679 (1-877-4-INFO-RX).

DPT:8055:50:1C:R1

117492-0917

Mylan.com

Manufacturer

Mylan Pharmaceuticals Inc.

Active Ingredients

Source

Drugs and Medications [223 Associated Drugs and Medications listed on BioPortfolio]

Clobetasol propionate [direct rx]

CLOBETASOL PROPIONATE- clobetasol propionate gel

Clobetasol propionate [renaissance pharma, inc.]

These highlights do not include all the information needed to use Clobetasol Propionate Foam safely and effectively. See full prescribing information for Clobetasol Propionate Foam.  Clobetasol Propi...

Clobetasol propionate [perrigo new york inc]

These highlights do not include all the information needed to use CLOBETASOL PROPIONATE FOAM safely and effectively. See full prescribing information for CLOBETASOL PROPIONATE FOAM. CLOBETASOL PROPION...

Clobetasol propionate [taro pharmaceuticals u.s.a., inc.]

These highlights do not include all the information needed to use CLOBETASOL PROPIONATE FOAM safely and effectively. See full prescribing information for CLOBETASOL PROPIONATE FOAM. CLOBETASOL PROPION...

Clobetasol propionate [mylan pharmaceuticals inc.]

These highlights do not include all the information needed to use CLOBETASOL PROPIONATE FOAM safely and effectively. See full prescribing information for CLOBETASOL PROPIONATE FOAM.  CLOBETASOL PROPI...

Clinical Trials [236 Associated Clinical Trials listed on BioPortfolio]

A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam

The primary objective of this study is to evaluate the efficacy and safety of clobetasol propionate 0.05% (Clobex®) spray compared to clobetasol propionate 0.05% (Olux®) foam.

Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis

This study is a comparison between Clobetasol Propionate Spray and Clobetasol Propionate Ointment with Regard to Efficacy, Safety, Subject Satisfaction and Duration of Response in Moderate...

Randomized Study to Compare the Bioavailability of Two Clobetasol Propionate 0.05% Topical Foams

The purpose of this study was to compare the relative vasoconstrictive effects of test and reference Clobetasol Propionate 0.05% Topical Foam in healthy, female subjects.

Pivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects

To compare the relative vasoconstrictive effects of two topical clobetasol propionate 0.05% lotions in asymptomatic subjects.

A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis

The purpose of the study is to determine the efficacy and safety of two different forms of a topical steroid (clobetasol propionate) in patients with plaque-type psoriasis.

PubMed Articles [103 Associated PubMed Articles listed on BioPortfolio]

Glucocorticoid mixtures of fluticasone propionate, triamcinolone acetonide and clobetasol propionate induce additive effects in zebrafish embryos.

Many synthetic glucocorticoids from medical applications occur in the aquatic environment. Whether they pose a risk for fish health is poorly known. Here we investigate effects of glucocorticoids flut...

Evaluation of the effectiveness of treatment of vulvar lichen sclerosus et atrophicus. Analysis of own material and review of the literature.

The study group included eleven female patients aged 18-77 years with a diagnosis of lichen sclerosus. Basic therapy consisted in the application of clobetasol in the first month and then once a day f...

Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study.

Pyoderma gangrenosum is a painful ulcerating disease. The current evidence base for treatment is limited. In a large prospective study of topical treatments, 44% of patients were healed by 6 months. U...

A Persistence Detector for Metabolic Network Rewiring in an Animal.

Biological systems must possess mechanisms that prevent inappropriate responses to spurious environmental inputs. Caenorhabditis elegans has two breakdown pathways for the short-chain fatty acid propi...

Scalp Sarcoidosis Presenting as Cicatricial Alopecia.

Sarcoidosis is a granulomatous condition that has a highly variable presentation. One rare presentation of sarcoidosis is cutaneous scalp sarcoidosis. Usually scalp sarcoid presents as a scarring alop...

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Endocrinology
Diabetes Diabetes Endocrine Disorders Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several g...

Dermatitis
Dermatitis means an inflammation of the skin. Contact dermatitis is a term used when this inflammation is caused by contact with something in the environment. The changes of dermatitis seen in the skin take the form of eczema; hence it may sometimes be r...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record